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was associated with induction of T-cell immunity against
viral antigens and reduction of hepatic expression of Foxp3.
Studies performed to elucidate the rational behind the lack
of antiviral activity of IL-12 in animals with high viremia
showed that the presence of high amounts of WHV-DNA in
serum is associated with the absence of IL-12-responsiveness
in vitro. In conclusion, IL-12-based gene therapy is an
efﬁcient approach to treat chronic hepadnavirus infection
in all cases with viral load below 1010 vg/ml, which is the
situation of most patients with chronic hepatitis B. The
elucidation of the precise mechanisms responsible for the
lack of response to IL-12 in animals with high viral load
will be important for the development of more efﬁcient
therapies against chronic hepatitis infection.
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Persistent viral infection in liver is still a global threat to
human health. It has been suggested that compromised
immune responses play a critical role for chronic viral
infection. It is, at least in part, shown that impaired
innate and adaptive immunity as well as liver tolerance
are responsible for the compromised immune responses,
but the underlying cellular and molecular mechanisms
remain largely undeﬁned. Recent studies have suggested
that CD4+CD25+ regulatory T-cells (Treg) are increased and
linked to compromised immune responses in patients with
hepatocellular carcinoma (HCC). This study attempts to
further characterize CD4+CD25+FoxP3+ Treg in blood, tumor
and non-tumor liver tissues of HCC patients, and understand
how the Treg affect immune responses and contribute
to disease progression. One-hundred and nineteen HCC
patients with chronic hepatitis B virus (HBV) infection
(designated as HBV-related HCC patients), 21 HBV-related
liver cirrhosis (LC) patients, and 47 normal controls
were enrolled. Flow cytometric, immunohistochemical, and
immunosuppressive assays were employed for analyses of
property of Treg. Multivariate analysis of prognostic factors
for overall survival was made using Cox’s proportional
hazards model. Circulating CD4+CD25+FoxP3+ Treg frequency
was signiﬁcantly increased and correlated with disease
progression in HCC patients. An abundant accumulation
of Treg concurrent with signiﬁcantly reduced inﬁltration of
CD8+ T-cells was found in tumor regions compared with non-
tumor regions. Granzyme A, B and perforin expressions were
dramatically decreased in tumor-inﬁltrating CD8+ T-cells.
Furthermore, Treg of HCC patients inhibited proliferation,
activation, degranulation, and production of Granzyme A,
B and perforin of CD8+ T-cells induced by anti-CD3/CD28
antibodies. Importantly, increased numbers of circulating
Treg were associated with high mortality and reduced
survival time of HCC patients.
Conclusion: Increased CD4+CD25+FoxP3+ Treg may impair
CD8+ T-cell function, promote disease progression and
represent both a potential prognostic marker and a
therapeutic target for HBV-related HCC individuals.
